Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study.People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...